8-Aminoadenosine (8-NH2-Ado) is an RNA-directed nucleoside analogue that effectively diminishes cellular ATP levels and impedes mRNA synthesis. It also obstructs Akt/mTOR signaling, inducing autophagy and apoptosis in a p53-independent manner. Its significant antitumor activity underscores its therapeutic potential.

8-Aminoadenosine (8-NH2-Ado) demonstrates a range of bioactive effects across various cell lines. In MM.1S and U266 cells, it exhibits half-maximal inhibitory concentrations (IC50s) of 1.5 μM and 8.88 μM, respectively, after a 48-hour exposure[1]. At a concentration of 10 μM over 24 hours, it induces significant apoptotic death of MCF-7 cells through a p53-independent mechanism, characterized by PARP cleavage[2]. Additionally, at a concentration of 3 μM, 8-Aminoadenosine triggers autophagy in MM.1S cells within 0.5 to 4 hours, and notably reduces ATP levels and glucose consumption over similar durations[1]. This compound also causes a marked time-dependent decrease in GLUT1 expression initially, with subsequent down-regulation of both GLUT1 and GLUT4 transporters over a longer period (24 hours)[1]. It is observed to inhibit cell proliferation and induce cell death without activating p53 pathway targets or increasing p53 or p21 proteins. Its toxicological actions are adenosine kinase activity-dependent, requiring conversion to 8-NH2-ATP in specifically adenosine kinase-deficient cells[1]. Analysis of cell viability and apoptosis under various concentrations and timeframes further corroborates its impact on cell survival and apoptotic pathways[1][2].